NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
Clinical Trials
5 trialsNCT06957431 2025-10-24
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University School of Medicine
Phase 1 Recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting